



Diamond Biofund
鑽石生技投資股份有限公司

2023 Q4 Online Investor Conference



TWSE: 6901

Disclaimer

- **The forward-looking statement in this presentation, including operational outlook, financial statements, and business forecasts, is based on internal data and the overall economic situation. The actual operational results, financial condition, and business outcomes in the future may differ from the predictive information. This variance could be attributed to various factors, including but not limited to operational and research risks associated with the Company's investment portfolios, changes in capital market trends, alterations in policies, laws, and financial economic conditions, as well as other uncontrollable risk factors.**
- **The Company's primary investment focus is in the biotechnology industry, where stock prices and fair values are significantly influenced by research outcomes, leading to substantial fluctuations. Consequently, a decrease in fair value may result in negative operating income.**
- **As a venture capital company primarily invested in the biotechnology industry, the Company's business nature involves lengthy development cycles, extensive capital investment, and no guaranteed success. Investors are advised to exercise special caution and diligence when considering investment.**

President's Remarks

Agenda

- I. Third Quarter 2023 Financial Results**
- II. Portfolio Updates and Introduction of New Portfolio Companies**
- III. Corporate Goals and Strategic Planning for Year 2024**

Revenue Recognition

Revenue includes realized and unrealized valuation gains and losses of the portfolios. The valuation approach varies per the type of portfolio.

Portfolio Traded Actively in Capital Market(s)	Portfolio Not Traded Actively or Not in Capital Market(s)
Quoted price as of valuation day	Valuation per modeling

Note 1: Closing price as of valuation day for TWSE/TPEX-listed shares

Note 2: Average trading price as of valuation day for TPEX Emerging Stock Board shares actively traded

Note 3: Valuation per modeling for TPEX Emerging Stock Board shares not actively traded

3Q'23 Financial Results

Unit: NT\$1,000

Item	2023 Q3	2022 Q3	2023 Q1-Q3	2022 Q1-Q3
Revenue	(1,255,392)	1,324,434	(2,653,927)	2,045,875
Net Income (Loss)	(1,310,193)	1,276,867	(2,774,809)	1,853,962
Earnings (Loss) per Share	NT\$(1.71)	NT\$1.70	NT\$(3.67)	NT\$2.47

Note 1 : Revenue includes realized and unrealized gain/loss of financial assets

Note 2 : 2022 EPS after retroaction of share dividend issued in 2023

Unit: NT\$1,000

Item	2023/09/30	2022/9/30
Paid-in Capital	8,493,000	5,000,000
Financial Assets at Fair Value through Profit or Loss	8,230,582	11,971,835
Cash and Cash Equivalent	4,479,282	425,781


Investment Portfolio

Unit: NT\$1,000

	Portfolio	Market	Changes in fair value in October 2023	Changes in fair value in November 2023
1	Oneness Biotech Co., Ltd.	TPEX Listed	546,554	228,790
2	CHO Pharma Inc.	TPEX Emerging Stock	(196,327)	(168,236)
3	Sinew Pharma Inc.	TPEX Emerging Stock	(51,650)	40,956
4	StemCyte International Ltd.	Non-public	(63,673)	223,350
5	Original BioMedicals Co., Ltd.	Non-public	3,563	17,983
6	Theia Medical Technology Co. Ltd.	Non-public	1,091	(2,205)
7	EyeYon Medical Ltd.	Non-public	126	(3,228)
8	Tetanti AgriBiotech Inc.	Non-public	(9,243)	316
9	Kendall Capital Partners I, L.P	Non-public	1,099	(3,207)
10	Bilayer Therapeutics, Inc.	Non-public	(3,957)	(40)
11	ImmunAdd Inc.	Non-public	0	0
12	Syncell Inc.	Non-public	700	(4,680)
13	Others	Non-public	155	(1,170)
	Total		228,438	328,629

Diamond Biofund I & II

Investor & Fund Management



The two new companies are independently managed and will conduct investments separately in different stages of biotechnologies or product development.

Agenda

- I. Third Quarter 2023 Financial Results
- II. Portfolio Updates and Introduction of New Portfolio Companies**
- III. Corporate Goals and Strategic Planning for Year 2024

Portfolios

Innovation New Drug

- Oneness Biotech
- CHO Pharma
- Sinew Pharma
- ImmunAdd

Cell Therapy, Gene Therapy, Drug Delivery

- StemCyte
- Rejuvenate Bio
- Bilayer Therapeutics
- Original BioMedicals

Advanced Medical Device, Research Equipment, Agricultural Biotechnology, & Others

- Theia
- EyeYon
- Syncell
- Tetanti AgriBiotech
- KCP Fund I

4Q'23 New Investment

Syncell

- **Type: New case**
- **Sector: Research equipment**
- **Location: KY (US 、 TW)**
- **Date: 2023/10**
- **Amount invested: US \$4M**
- **Amount raised: US \$8M**
- **Structure: Convertible notes**

StemCyte

- **Type: Existing case**
- **Sector: Cell therapy**
- **Location: KY (US, TW, India)**
- **Date: 2023/11**
- **Amount invested: US \$6.35M**
- **Amount raised: US \$25.27M**
- **Structure: Common stock**

Syncell - Introduction

- Spin-off from Academia Sinica in 2020.
- Established in 2021, Syncell Inc. was based in Cayman, and 100% holds subsidiaries in Taiwan and in the United States. Research and development teams in Taiwan and sales teams in the United States have been established.
- The world's first in-cell "pickable" microscope has completed product development and been commercialized in 2023.
- Key products include microscope, reagents and proteomics analysis services.



Syncell - Highlight

- **In spatial proteomics, the technology is the only label-free approach capable of capturing unknown proteins.**
- **Product development has been completed and there is proven sales.**
- **A sales team familiar with the U.S. market has been established.**
- **Key players in the field have initiated discussions with Syncell for exclusive distribution.**
- **Potential acquisition by key players or an IPO shortly after obtaining a successful sales track record.**

StemCyte - Introduction

- **StemCyte International, Ltd., a Cayman-based holding company, 100% holds subsidiaries in Taiwan and the United States, and has operational presence in the United States, Taiwan, and India.**
- **It ranks among the top ten global cord blood cell banking companies, specializing in both stem cell and immune cell therapies. StemCyte is currently the only company in Taiwan holding dual certifications from the American Association of Blood Banks (AABB) and the Foundation for the Accreditation of Cellular Therapy (FACT). It is also one of the few private enterprises capable of providing both public and private cord blood banking services.**
- **Substantial progress has been made in several research and development projects, including the ongoing FDA review of the first cord blood Biologics License Application (BLA) in the United States, two ongoing Phase II clinical trials, and the completion of one Phase I clinical trial.**

StemCyte - Highlight

- **Ranked among the top ten global cord blood cell banking companies, specializing in both stem cell and immune cell therapy technologies.**
- **The first company to receive FDA approval for a clinical trial using cord blood to treat spinal cord injuries and long COVID.**
- **Anticipate to obtain FDA BLA approval in the first half of 2024.**
- **Planning to submit listing on the TWSE Innovation Board in 2024.**

Agenda

- I. Third Quarter 2023 Financial Results
- II. Portfolio Updates and Introduction of New Portfolio Companies
- III. Corporate Goals and Strategic Planning for Year 2024**

Strategic Alliances

**Alliance with Global
Renowned Investment
Institutions**

**Alliance with Top-tier
International Academic
Research Institutions**

- ✓ **Accelerate in-depth collaboration in technologies and products**
- ✓ **Promote flagship biotech investment projects**

Example: DCI Partners

Through licensing deals, equity investments, or acquisition of business rights, we will create investment position in key fields such as cell therapy, nucleic acid drugs, etc.

A Platform Bridging Innovation to Market



- Acting as a **vital catalyst connecting the innovation with global sales market and commercialization** to maximize the asset value.

A Platform Directing Investment to Capital Market



- Introducing **global competitive technology platforms or assets into Taiwan capital market:**

Expedite the product development and elevate investment synergies by leveraging Taiwan's outstanding clinical medical capabilities and integrating resources.

Investments in Full Development Cycle

Diamond Biofund Inc.

Evergreen VC

Early-stage

Diamond Biofund II Inc.

Investment Horizon of 8-10 years

Mid/Late-stage

Diamond Biofund I Inc.

Commercial-stage

Incorporating External Capital ♦ Expanding Investment Scale

Investment Scope

- **Innovative technologies, platforms, and business models with worldclass competitiveness**
- **First-in-class or best-in-class novel drugs addressing unmet medical needs**
- **Innovative, high-end and market-ready medical devices**
- **Advanced drugs optimizing cancer treatment through immune modulation checkpoints**
- **Key technologies and therapeutic drugs related to nucleic acid target delivery**
- **New drugs, medical devices, or medical foods related to microbiome, specific strains, and their metabolic products**
- **Collaboration or mergers involving the aforementioned technologies, products, and enterprises**

Diamond Biofund II Inc.

Mid/Late-stage

“Company” with advanced technology, market opportunities

- Clear regulatory certification pathway
- Initial efficacy proof
- Potential for capital market or acquisition

Verified, highly innovative “Asset”

- Projects addressing clinical and market needs
- Assets and patents with transaction value
- Commercial rights with market value

Diamond Biofund I Inc.

Commercial-stage

A “Channel” or “Pharmaceutical”
company selling biomedical products

- Sales team with proven track record and comprehensive channel distribution to enhance product portfolio and create value.

Commercialized “Innovative
Products” or “Business Models”

- Integrate commercial products or business services into existing channels to create market value and accelerate market entry.

Investment Strategy

Company	Development Stage	Target Characteristics		Profit Models
Diamond Biofund	Early-stage	<ul style="list-style-type: none"> Technology platforms Patent rights 	<ul style="list-style-type: none"> Other innovative applications 	<ul style="list-style-type: none"> Integration & transformation Out-licensing M&A IPO
Diamond II	Mid/Late-stage	<ul style="list-style-type: none"> Technology platforms Patent rights Clinical new drugs 	<ul style="list-style-type: none"> Approved medical devices Commercial rights Other innovative applications 	
Diamond I	Commercial-stage	<ul style="list-style-type: none"> Sales channels Medical services 	<ul style="list-style-type: none"> Approved drugs Marketed medical devices 	



Diamond Biofund
鑽石生技投資股份有限公司

Invest in Diamond Biofund, Invest in Biotech Elites